Lipocalin-2 and matrix metalloproteinase-9 expression in high-grade endometrial cancer and their prognostic value

Histopathology

Volumn 67, Issue 2, 2015, Pages 206-215

  Mihalj SrdeliĆ, Sanja ^a   Kuzmić Prusac, Ivana ^a   Zekić Tomaš, Sandra ^a   Šamija Projić, Ivana ^b   Čapkun, Vesna ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Endometrial cancer; Lipocalin 2; Matrix metalloproteinase 9; Survival

Indexed keywords

ANTIBODY; GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PARAFFIN; ACUTE PHASE PROTEIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; MMP9 PROTEIN, HUMAN; ONCOPROTEIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STAINING; SURVIVAL ANALYSIS; TUMOR INVASION; VASCULAR DISEASE; AGE; CANCER GRADING; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; GENE EXPRESSION; HYSTERECTOMY; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE;

ACUTE-PHASE PROTEINS; AGE FACTORS; AGED; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; HYSTERECTOMY; IMMUNOENZYME TECHNIQUES; LIPOCALINS; MATRIX METALLOPROTEINASE 9; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84923170065     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12633     Document Type: Article

References (40)

1. Memon A. Epidemiology of gynaecological cancers. In Shafi M, Earl H, Tan L eds. Gynaecological oncology. Cambridge: Cambridge University Press, 2010; 1-13.
2. Hacker N, Friedlander M. Uterine cancer. In Berek J, Hacker N eds. Berek and Hacker’s gynaecology. 5th ed. Baltimore: Lippincott Wiliams & Wilkins, 2010; 396-442.
3. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol. 1982; 6; 93-108.
4. Slomovitz BM, Burke TW, Eifel PJ et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol. Oncol. 2003; 91; 463-469.
5. Nicklin JL, Copeland LJ. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin. Obstet. Gynecol. 1996; 39; 686-695.
6. Flower DR. The lipocalin protein family: structure and function. Biochem. J. 1996; 318; 1-14.
7. Devireddy LR, Teodoro JG, Richard FA, Green MR. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 2001; 293; 829-834.
8. Bratt T. Lipocalins and cancer. Biochim. Biophys. Acta 2000; 1482; 318-326.
9. Nilsen-Hamilton M, Liu Q, Ryon J, Bendickson L, Lepont P, Chang Q. Tissue involution and the acute phase response. Ann. N. Y. Acad. Sci. 2003; 995; 94-108.
10. Triebel S, Blaser J, Reinke H, Tschesche H. A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 1992; 314; 386-388.
11. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 1993; 268; 10425-10432.
12. Friedl A, Stoesz SP, Buckley P et al. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem. J. 1999; 31; 433-441.
13. Nielsen BS, Borregaard N, Bundgaard JR et al. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996; 38; 414-420.
14. Tong Z, Wu X, Ovcharenko D et al. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem. J. 2005; 391; 441-448.
15. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res. Treat. 2008; 108; 389-397.
16. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, Gould MN. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int. J. Cancer 1998; 79; 565-572.
17. Cho H, Kim JH. Lipocalin 2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J. Histochem. Cytochem. 2009; 57; 513-521.
18. Mannelqvist M, Stefansson IM, Wik E et al. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer 2012; 12; 169.
19. Barresi V, Reggiani-Bonetti L, Di Gregorio C, Vitarelli E, Ponz De Leon M, Barresi G. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma. Pathol. Res. Pract. 2011; 207; 479-486.
20. Linnerth NM, Sirbovan K, Moorehead RA. Use of a transgenic mouse model to identify markers of human lung tumors. Int. J. Cancer 2005; 114; 977-982.
21. Moniaux N, Chakraborty S, Yalniz M et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br. J. Cancer 2008; 98; 1540-1547.
22. Zhang H, Xu L, Xiao D, Xie J, Zeng H, Wang Z. Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumor invasion. J. Clin. Pathol. 2007; 60; 555-561.
23. Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, Van Dujin W, Zuidwijk K. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur. J. Cancer 2007; 43; 1869-1876.
24. Lee HJ, Lee EK, Lee KJ, Hons SW, Yoon Y, Kim JS. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int. J. Cancer 2006; 118; 2490-2497.
25. Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW. Neutrophil gelatinase-associated lipocalin (NGAL) is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int. J. Cancer 2007; 120; 2426-2434.
26. Tong Z, Kunnumakkara AB, Wang H, Matsuo Y, Diagaradjane P, Harikumar KB. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008; 68; 6100-6108.
27. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin. Cancer Res. 2005; 11; 5390-5395.
28. Smith ER, Zurakowski D, Saad A, Scot RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin. Cancer Res. 2008; 14; 2378-2386.
29. Yan L, Borregaard N, Kjeldsen H, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinaseassociated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 2001; 276; 37258-37265.
30. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002; 2; 161-174.
31. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 2000; 10; 415-433.
32. Karahan N, Güney M, Baspinar S, Oral B, Kapucuoglu N, Mungan T. Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 2007; 28; 184-188.
33. Iurlaro M, Loverro G, Vacca A et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and-9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur. J. Clin. Invest. 1999; 29; 793-801.
34. Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P, Daraï E. Metalloproteinase-2,-7 and-9 and tissue inhibitor of metalloproteinase-1 and-2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann. Oncol. 2006; 17; 637-644.
35. Fang Y, Qingping J, Ying Z et al. Abnormal expression of matrix metalloproteinase-9 (MMP-9) correlates with clinical course in Chinese patients with endometrial cancer. Dis. Markers 2012; 32; 321-327.
36. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 2009; 105; 103-104.
37. Miyamoto T, Kashima H, Suzuki A et al. Laser-captured microdissection-microarray analysis of the genes involved in endometrial carcinogenesis: stepwise up-regulation of lipocalin-2 expression in normal and neoplastic endometria and its functional relevance. Hum. Pathol. 2011; 42; 1265-1274.
38. Miyamoto T, Asaka R, Suzuki A, Takatsu A, Kashima H, Shiozawa T. Immunohistochemical detection of a specific receptor for lipocalin-2 (solute carrier family 22 member 17, SLC22A17) and its prognostic significance in endometrial carcinoma. Exp. Mol. Pathol. 2011; 91; 563-568.
39. Rudd PM, Mattu TS, Masure S et al. Glycosylation of natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin. Biochemistry 1999; 38; 13937-13950.
40. Zuo JH, Zhu W, Li MY et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J. Cell. Biochem. 2011; 112; 2508-2517.